Listen and follow our podcasts on:

Eisai Europe Ltd

Prof. Josep Llovet and Prof. Stephen L. Chan discuss which patients can benefit, and they provide guidance on implementation of dosing strategies and patient pre-habilitation, for prediction of efficacy and toxicity.

 

In this podcast, Prof. Josep Llovet and Prof. Stephen L. Chan describe patients who can benefit from monotherapy, and they  share current guidance on implementation of dosing strategies for the management of toxicity in clinical practice. They discuss first line monotherapy with TKI (lenvatinib or sorafenib) for patients who are not suitable for the treatment with atezo-bev combination (around 20% of the patients), which is the current standard of care. They summarize the HCC patients who are not ideal for this I/O combination, such as HCC patients with liver transplantation, high bleeding risk, impaired liver function or severe autoimmune disease.

 

The experts discuss which patients can benefit from TKI and provide a summary of efficacy and safety data from several pivotal clinical studies (including SHARP, REFLECT, IMbrave150), as well as real-world data. Dosing strategies for VEGFR-TKIs and management of AEs are discussed, as well as guideline recommendations. Finally, the experts anticipate key developments over the next few years, focusing on the new immunotherapy combinations that could become new standard of care.

 

This HCC CONNECT podcast is also available on
Castos, Spotify, Apple Podcasts, and Google Podcasts.

Prof. Josep Llovet has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Bristol-Myers Squibb, Boehringer-Inelheim, Eisai Inc, Eli Lilly and Ipsen. 

Prof. Stephen L. Chan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astra-Zeneca, MSD, Eisai and BMS 

Listen and follow our podcasts on:

Eisai Europe Ltd

Prof. Josep Llovet and Prof. Stephen L. Chan discuss which patients can benefit, and they provide guidance on implementation of dosing strategies and patient pre-habilitation, for prediction of efficacy and toxicity.

 

In this podcast, Prof. Josep Llovet and Prof. Stephen L. Chan describe patients who can benefit from monotherapy, and they  share current guidance on implementation of dosing strategies for the management of toxicity in clinical practice. They discuss first line monotherapy with TKI (lenvatinib or sorafenib) for patients who are not suitable for the treatment with atezo-bev combination (around 20% of the patients), which is the current standard of care. They summarize the HCC patients who are not ideal for this I/O combination, such as HCC patients with liver transplantation, high bleeding risk, impaired liver function or severe autoimmune disease.

 

The experts discuss which patients can benefit from TKI and provide a summary of efficacy and safety data from several pivotal clinical studies (including SHARP, REFLECT, IMbrave150), as well as real-world data. Dosing strategies for VEGFR-TKIs and management of AEs are discussed, as well as guideline recommendations. Finally, the experts anticipate key developments over the next few years, focusing on the new immunotherapy combinations that could become new standard of care.

 

This HCC CONNECT podcast is also available on
Castos, Spotify, Apple Podcasts, and Google Podcasts.

Prof. Josep Llovet has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Bristol-Myers Squibb, Boehringer-Inelheim, Eisai Inc, Eli Lilly and Ipsen. 

Prof. Stephen L. Chan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astra-Zeneca, MSD, Eisai and BMS 

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe Ltd
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

publication Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
video Video
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
interactive-patient-case Interactive patient case
Oncology 
NTRK fusion testing and treatment in pediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
interactive-patient-case Interactive patient case
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
DiCE ICAN international cancer advocacy network
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025

Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Prof. Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED